Calcium-regulated parathyroid hormone secretion in adynamic renal osteodystrophy.

[1]  Y. Pei,et al.  Risk factors for renal osteodystrophy: A multivariant analysis , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  G. Segre,et al.  Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism. , 1994, The American journal of physiology.

[3]  P. Messa,et al.  Direct in vivo assessment of parathyroid hormone-calcium relationship curve in renal patients. , 1994, Kidney international.

[4]  G. Segre,et al.  Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. , 1994, Kidney international.

[5]  H. Malluche,et al.  Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. , 1994, Kidney international.

[6]  D. Sherrard,et al.  Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. , 1993, Kidney international.

[7]  J. Gornbein,et al.  Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. , 1993, The Journal of clinical endocrinology and metabolism.

[8]  F. Malberti,et al.  Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol. , 1993, Kidney international. Supplement.

[9]  J. Cunningham,et al.  Parathyroid sensing of the direction of change of calcium in uremia. , 1993, Kidney international.

[10]  F. Llach,et al.  Parathyroid gland function in chronic renal failure. , 1993, Kidney international.

[11]  C. Hassager,et al.  Heterogeneous response to calcium by individual parathyroid cells. , 1993, The Journal of clinical investigation.

[12]  Y. Pei,et al.  The spectrum of bone disease in end-stage renal failure--an evolving disorder. , 1993, Kidney international.

[13]  M. Monier‐Faugere,et al.  Risk of adynamic bone disease in dialyzed patients. , 1992, Kidney international. Supplement.

[14]  U. Gladziwa,et al.  Immunoreactive parathyroid hormone after volume change in normo- and hypotensive hemodialysis patients. , 1992, Clinical nephrology.

[15]  F. Llach,et al.  The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. , 1991, Journal of the American Society of Nephrology : JASN.

[16]  J. Bourdeau,et al.  Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  E. Brown,et al.  Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. , 1991, Physiological reviews.

[18]  R. Kineman,et al.  Bovine pituitary cells exhibit a unique form of somatotrope secretory heterogeneity. , 1990, Endocrinology.

[19]  R. Dunlay,et al.  Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. , 1989, Kidney international.

[20]  J. Delmez,et al.  Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. , 1989, The Journal of clinical investigation.

[21]  W. Goodman,et al.  Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. , 1988, Kidney international.

[22]  Brennan,et al.  Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. , 1987, Clinical chemistry.

[23]  P Zucchelli,et al.  Inorganic Phosphate Removal during Different Dialytic Procedures , 1987, The International journal of artificial organs.

[24]  E. Brown,et al.  Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. , 1983, The Journal of clinical endocrinology and metabolism.

[25]  P. Keshaviah,et al.  The metabolic effects of hemodialysis with and without glucose in the dialysate. , 1978, The American journal of clinical nutrition.

[26]  D. Rodbard,et al.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. , 1978, The American journal of physiology.

[27]  C. Kjellstrand,et al.  Osmolality changes during hemodialysis. Natural history, clinical correlations, and influence of dialysate glucose and intravenous mannitol. , 1977, Annals of internal medicine.

[28]  A. Torres,et al.  Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  G. Segre,et al.  Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. , 1994, Kidney international.

[30]  B. Boudailliez,et al.  Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment? , 1992, Bone.

[31]  R. Dunlay,et al.  A comparison of parathyroid-gland function in haemodialysis patients with different forms of renal osteodystrophy. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  R. Horst,et al.  A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. , 1984, The Journal of clinical endocrinology and metabolism.